Stocks

Zura Bio launches global Phase 2 TibuSURE study evaluating tibulizumab

December 23, 2024 — 06:55 am EST

Written by TheFly for TipRanks->

Zura Bio (ZURA) announced the launch of TibuSURE, a Phase 2 global study evaluating tibulizumab for the treatment of systemic sclerosis in adults.

Don't Miss Our Christmas Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on ZURA:

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

Stocks
TipRanks
TipRanks is the most comprehensive data set of sell side analysts and hedge fund managers. TipRanks' multi-award winning platform ranks financial experts based on measured performance and the accuracy of their predictions so investors know who to trust when making investment decisions.
More articles by this source->

Stocks mentioned

ZURA

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

  • •

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.